Traphaco JSC

VN:TRA Vietnam Drug Manufacturers - Specialty & Generic
Market Cap
$113.87 Million
₫2.89 Trillion VND
Market Cap Rank
#24004 Global
#188 in Vietnam
Share Price
₫69800.00
Change (1 day)
+1.16%
52-Week Range
₫65900.00 - ₫77300.00
All Time High
₫103027.02
About

Traphaco Joint Stock Company, together with its subsidiaries, produces and trades in pharmaceutical products, chemicals, and medical supplies and equipment in Vietnam. The company offers medical supplies; antipyretics; medicines for the hair, eyes, central neutral system, respiratory system, and liver; and other products. It is also involved in the production of medicines to treat human diseases,… Read more

Traphaco JSC (TRA) - Net Assets

Latest net assets as of December 2025: ₫1.69 Trillion VND

Based on the latest financial reports, Traphaco JSC (TRA) has net assets worth ₫1.69 Trillion VND as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₫2.34 Trillion) and total liabilities (₫653.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₫1.69 Trillion
% of Total Assets 72.08%
Annual Growth Rate 7.09%
5-Year Change 33.03%
10-Year Change N/A
Growth Volatility 2.44

Traphaco JSC - Net Assets Trend (2019–2025)

This chart illustrates how Traphaco JSC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Traphaco JSC (2019–2025)

The table below shows the annual net assets of Traphaco JSC from 2019 to 2025.

Year Net Assets Change
2025-12-31 ₫1.69 Trillion +10.02%
2024-12-31 ₫1.53 Trillion +2.93%
2023-12-31 ₫1.49 Trillion +7.86%
2022-12-31 ₫1.38 Trillion +8.92%
2021-12-31 ₫1.27 Trillion +8.11%
2020-12-31 ₫1.17 Trillion +4.87%
2019-12-31 ₫1.12 Trillion --

Equity Component Analysis

This analysis shows how different components contribute to Traphaco JSC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 27.4% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings ₫343.08 Billion 22.09%
Other Components ₫1.21 Trillion 77.91%
Total Equity ₫1.55 Trillion 100.00%

Traphaco JSC Competitors by Market Cap

The table below lists competitors of Traphaco JSC ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Traphaco JSC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,419,377,490,742 to 1,552,838,881,560, a change of 133,461,390,818 (9.4%).
  • Net income of 249,679,317,003 contributed positively to equity growth.
  • Dividend payments of 154,726,103,809 reduced retained earnings.
  • Other factors increased equity by 38,508,177,624.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income ₫249.68 Billion +16.08%
Dividends Paid ₫154.73 Billion -9.96%
Other Changes ₫38.51 Billion +2.48%
Total Change ₫- 9.40%

Book Value vs Market Value Analysis

This analysis compares Traphaco JSC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.86x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.80x to 1.86x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 ₫24884.31 ₫69800.00 x
2020-12-31 ₫26037.58 ₫69800.00 x
2021-12-31 ₫28182.60 ₫69800.00 x
2022-12-31 ₫30762.03 ₫69800.00 x
2023-12-31 ₫33276.39 ₫69800.00 x
2024-12-31 ₫34242.68 ₫69800.00 x
2025-12-31 ₫37462.45 ₫69800.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Traphaco JSC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 16.08%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.30%
  • • Asset Turnover: 1.15x
  • • Equity Multiplier: 1.51x
  • Recent ROE (16.08%) is below the historical average (18.12%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 14.87% 8.97% 1.09x 1.52x ₫50.28 Billion
2020 18.14% 10.26% 1.16x 1.53x ₫87.86 Billion
2021 20.68% 11.18% 1.27x 1.46x ₫124.77 Billion
2022 21.11% 11.22% 1.32x 1.42x ₫141.63 Billion
2023 19.09% 11.45% 1.08x 1.54x ₫125.32 Billion
2024 16.84% 10.18% 1.08x 1.53x ₫97.08 Billion
2025 16.08% 9.30% 1.15x 1.51x ₫94.40 Billion

Industry Comparison

This section compares Traphaco JSC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,052,983,759,522
  • Average return on equity (ROE) among peers: 17.00%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Traphaco JSC (TRA) ₫1.69 Trillion 14.87% 0.39x $27.57 Million
Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) $1.66 Trillion 16.57% 0.36x $183.29 Million
DHG Pharmaceutical JSC (DHG) $3.57 Trillion 20.74% 0.25x $29.78 Million
DOMESCO Medical Import Export JSC (DMC) $1.25 Trillion 18.58% 0.22x $21.40K
Imexpharm Corp (IMP) $1.73 Trillion 12.12% 0.21x $119.65 Million